Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Treatment Options for Ovarian Low Malignant Potential Tumors
A link to a list of current clinical trials is included for each treatment section. For some stages, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Early Stage Ovarian Low Malignant Potential Tumors (Stage I and II)Surgery is the standard treatment for early stage ovarian low malignant potential tumor. The type of surgery usually depends on whether a woman plans to have children.For women who plan to have children, surgery is either:unilateral salpingo-oophorectomy; orpartial oophorectomy.To prevent recurrence of disease, most doctors recommend surgery to remove the remaining ovarian tissue when a woman no longer plans to have children.For women who do not plan to have children, treatment may be hysterectomy and bilateral salpingo-oophorectomy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage I borderline ovarian surface epithelial-stromal
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - To Learn More About Ovarian Germ Cell Tumors
For more information from the National Cancer Institute about ovarian germ cell tumors, see the following:Ovarian Cancer Home PageDrugs Approved for Ovarian CancerFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in
Ovarian Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Who Is at Risk?
Ovarian cancer is rare. The incidence rate for ovarian cancer between 2006 and 2010 was 12.5 cases per 100,000 women. Women with a family history of ovarian cancer are at increased risk, and those with an inherited predisposition to ovarian cancer, such as a BRCA1 or BRCA2 mutation, have a very high risk of developing ovarian cancer (refer to the Lynch syndrome section in the PDQ summary on Genetics of Breast and Ovarian Cancer for more information). Other risk factors for ovarian cancer include obesity, nulliparity and use of postmenopausal hormone therapy, fertility drugs, and perineal talc. Factors associated with a decreased risk of ovarian cancer include use of oral contraceptives, multiple pregnancies, breast-feeding, and tubal ligation.[2,3,4,5]References: Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review, 1975-2010. Bethesda, Md: National Cancer Institute, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Also
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (09 / 02 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Stage I and Stage II Ovarian Epithelial Cancer Treatment
Treatment options:If the tumor is well differentiated or moderately well differentiated, surgery alone may be adequate treatment for patients with stage IA and IB disease. Surgery should include hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Additionally, the undersurface of the diaphragm should be visualized and biopsied; pelvic and abdominal peritoneal biopsies and pelvic and para-aortic lymph node biopsies are required and peritoneal washings should be obtained routinely. In selected patients who desire childbearing and have grade I tumors, unilateral salpingo-oophorectomy may be associated with a low risk of recurrence.If the tumor is grade III, densely adherent, or stage IC, the chance of relapse and death from ovarian cancer is as much as 30%.[3,4,5,6] Clinical trials evaluating the following treatment approaches have been performed:Intraperitoneal P-32 or radiation therapy.[1,7,8]Systemic chemotherapy based on platinums alone or in combination with
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Recurrent Ovarian Low Malignant Potential Tumors
Ovarian low malignant potential tumors may recur (come back) after they have been treated. The tumors may come back in the other ovary or in other parts of the body.
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Treatment Option Overview
Standard treatment options for patients with ovarian germ cell tumors include:Surgery.Chemotherapy.Radiation therapy.Patients may be treated with unilateral salpingo-oophorectomy or total abdominal hysterectomy and bilateral salpingo-oophorectomy.All patients except those with stage I, grade I immature teratoma and stage IA dysgerminoma require postoperative chemotherapy. With platinum-based combination chemotherapy, the prognosis for patients with endodermal sinus tumors, immature teratomas, embryonal carcinomas, choriocarcinomas, and mixed tumors containing one or more of these elements has improved dramatically. As new and more effective drugs are developed, many of these patients will be candidates for newer clinical trials.Treatment options under clinical evaluation for patients with ovarian germ cell tumors include:High-dose chemotherapy with bone marrow transplant.New treatment options.References: Gershenson DM, Morris M, Cangir A, et al.: Treatment of malignant germ cell
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062968-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Low Malignant Potential Tumors Treatment